BioSpace News Archive

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it is enrolling patients into an open label extension to the ongoing LPCN 1144 Phase 2 LiFT study based on investigator and patient interest in continuing treatment. The LiFT (" Li ver

Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, Feb. 16, 2021. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Glenn David will review fourth quarter and full year 2020 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Z

- Cosmos Capital, a digital infrastructure provider, to become publicly traded through a business combination with Wize - The combined company is expected to have approximately US$5 million in cash and cash equivalents at closing

Therapeutic Solutions International, Inc., (OTC Markets: TSOI), reported today new data demonstrating a two-week course of QuadraMune™ increased immunological parameters relevant to antiviral immunity.

Omnia Medical, one of the fastest growing spine organizations in the United States, today announced the addition of Jennifer Martin and Dan Rogers to the Omnia Medical team.

Beta Bionics, Inc. — a medical technology company developing the iLet®, the world’s first fully automated bionic pancreas system — today announced that Beth Brooke has been appointed to the Company’s Board of Directors.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that on December 31, 2020, it will give notice of its intention to redeem the following Senior Notes, representing an aggregate total principal amount of approximately $2.6 billion, on January 15, 2021 (the “Redemption Date”):

HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it has received notification of the issuance of Canadian patent number 2877729 for “Nuclease Protection Methods for Detection of Nucleotide Variants.”

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology, today announced the appointment of Sean J. Shapiro as Vice President of Sales, effective January 1, 2021 .

CEL-SCI Corporation (NYSE American: CVM) reported financial results for the fiscal year ended September 30, 2020, as well as key clinical and corporate developments. Clinical and Corporate Developments included: During fiscal 2020, the Independent Data Monitoring Committee (IDMC) for the Company’s pivotal Phase 3 head and neck cancer study of Multikine* (Leukocyte Interleukin, Injection) conducted an official